Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Glaxo gets global rights to MorphoSys’ rheumatoid arthritis antibody MOR103

Executive Summary

MorphoSys AG (fully human antibody technologies) has granted GlaxoSmithKline PLC worldwide rights to its lead candidate MOR103, in Phase I/II for mild-to-moderate rheumatoid arthritis, and in Phase I for multiple sclerosis. MOR103 was renamed otilimab (GSK3196165).

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies